Obstacles in the Diagnostics and Therapy of Heparin-Induced Thrombocytopenia

被引:3
作者
Antonijevic, Nebojsa M. [1 ]
Radovanovic, Nebojsa [1 ]
Obradovic, Slobodan [2 ]
Vucelic, Dragica [5 ]
Stojanovic, Bojan [1 ]
Mikovic, Danijela [3 ]
Kovac, Mirjana [3 ]
Kocica, Tina [1 ]
Tadic, Svetlana [3 ]
Antonijevic, Irina [3 ]
Draskovic, Snezana [3 ]
Djordjevic, Valentina [4 ]
Calija, Branko [5 ]
Perunicic, Jovan [1 ]
Vasiljevic, Zorana [1 ]
机构
[1] Clin Ctr Serbia, Inst Cardiovasc Dis, Belgrade 11000, Serbia
[2] Mil Med Acad, Clin Emergency Med, Belgrade 11002, Serbia
[3] Blood Transfus Inst Serbia, Belgrade, Serbia
[4] Inst Mol Genet & Genet Engn, Belgrade 11001, Serbia
[5] Inst Cardiovasc Dis Dedinje, Belgrade, Serbia
关键词
heparin; induced; thrombocytopenia; MOLECULAR-WEIGHT HEPARIN; MANAGEMENT; FONDAPARINUX; ANTIBODIES; PATIENT; PROPHYLAXIS; RISK; HIT;
D O I
10.2298/SARH10S1069A
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
An immune-mediated, severe, acquired prothrombotic disorder, heparin-induced thrombocytopenia type II (HIT II) occurs in 0.5-5% of patients exposed to unfractionated heparin longer than 5-7 days. Arterial and venous thromboses are induced by HIT II in about 35-50% of patients. Typical death rate for HIT is about 29%, while 21% of HIT patients result in amputation of a limb. The trend towards the occurrence of HIT due to the administration of low molecular weight heparins (LMWH) taking ever conspicuous place in the standard venous thromboembolism (VTE) prophylaxis has been more frequently observed recently. It is considered that LMWH may cause HIT II in about 0.25-1%. The need for further modification of HIPA assays with LMWH has been imposed in the HIT laboratory diagnostics, heretofore overburdened with complexity. There are several constantly opposing problems arising in HIT laboratory diagnostics, one of which is that in a certain number of patients immunologic assays detect nonpathogenic antibodies (mainly IgM or IgA heparin-PF4 antibodies) while, on the other hand, the occurrence of HIT pathogenetically mediated by minor antigens (neutrophil-activating peptide 2 or interleukin 8) may be neglected in certain cases. The following factors play an important role in the interpretation of each laboratory HIT assays performed: 1. correlation with HIT clinical probability test, the best known of which is 4T'score, 2. the interpretation of the laboratory findings dependent on the time of the thrombocytopenia onset, as well as 3. the sensitivity and specificity of each test respectively. The HIT diagnostics in the presence of other comorbid states which may also induce thrombocytopenia, more precisely known as pseudo HIT (cancer, sepsis, disseminated intravascular coagulation, pulmonary embolism, antiphospholipid syndrome, etc), represents a specific clinical problem.
引用
收藏
页码:69 / 73
页数:5
相关论文
共 34 条
  • [1] Heparin induced thrombocytopenia: diagnosis and management update
    Ahmed, I.
    Majeed, A.
    Powell, R.
    [J]. POSTGRADUATE MEDICAL JOURNAL, 2007, 83 (983) : 575 - 582
  • [2] Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia
    Amiral, J
    MarfaingKoka, A
    Wolf, M
    Alessi, MC
    Tardy, B
    BoyerNeumann, C
    Vissac, AM
    Fressinaud, E
    Poncz, M
    Meyer, D
    [J]. BLOOD, 1996, 88 (02) : 410 - 416
  • [3] Antonijevic Nabojsa, 2004, Srp Arh Celok Lek, V132, P33
  • [4] Antonijevic Nebojsa, 2003, Med Pregl, V56, P247, DOI 10.2298/MPNS0306247A
  • [5] Salvage late plasmapheresis in a patient with pulmonary embolism caused by heparin-induced thrombocytopenia primarily resistant to danaparoid sodium and lepirudin
    Antonijevic, Nebojsa M.
    Savic, Nebojsa B.
    Perunicic, Jovan
    Kovac, Mirjana
    Mikovic, Danijela
    Stanojevic, Milica
    Calija, Branko
    Milosevic, Rajko A.
    Obradovic, Slobodan D.
    Vasiljevic, Zorana
    [J]. JOURNAL OF CLINICAL APHERESIS, 2006, 21 (04) : 252 - 255
  • [6] Need for more intensive treatment of patients with acute pulmonary embolism caused by heparin-induced thrombocytopaenia Type II
    Antonijevic, NM
    Milosevic, R
    Perunicic, J
    Stanojevic, M
    Calija, B
    Vasiljevic, Z
    [J]. EUROPEAN HEART JOURNAL, 2005, 26 (24) : 2745 - 2746
  • [7] Platelet factor 4/heparin antibody (IgG/M/A) in healthy subjects: a literature analysis of commercial immunoassay results
    Arepally, Gowthami M.
    Hursting, Marcie J.
    [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2008, 26 (01) : 55 - 61
  • [8] Cooney MF, 2006, CRIT CARE NURSE, V26, P30
  • [9] de Maistre E, 2006, CAN J ANAESTH, V53, pS123
  • [10] DLOTT JS, 2001, DISORDERS HEMOSTASIS, P425